Italy is the fourth country to start treating PROTECT patients. This also marks the 67th patient treated in the PROTECT study. Read more on APSS's website International Trial to Optimize Neoadjuvant Radiochemotherapy for Esophageal and Gastroesophageal Junction Cancer (“PROTECT”) now Open for Patient.

Facts

• PROton versus photon Therapy for Esophageal Cancer – a Trimodality strategy (PROTECT) compares the clinical outcomes of proton therapy and state-of-the-art photon radiotherapy for locally advanced esophageal cancer.
• The PROTECT study is developed by the European Particle Therapy Network (EPTN)
• A total of 396 patients are expected to be included in the randomized study, with completion expected by 2027.
• This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101008134. The JU receives support from the European Union’s Horizon 2020 research and innovation program, EFPIA, Varian - a Siemens Healthineers company, and IBA worldwide.

Further information

• Daniele Scartoni, Principal Investigator, APSS, Trento, IT.
  • Email: daniele.scartoni@apss.tn.it
• Frank Lohr, Head of Proton Therapy, APSS, Trento, IT.
  • Email: frank.lohr@apss.tn.it
• Marianne Nordsmark, Chief Investigator, Aarhus University Hospital, DK.
  • E-mail: protect@rm.dk
• Website: https://www.protect-trial.eu/